Collectively, these results suggest that BAY-I treatment not only directly inhibits Pten-null prostate cancer cell growth, but also triggers CD8+ T cell-dependent anti-tumor immunity and cancer cell killing effects. This evidence concerns the gene CD8A and prostate carcinoma.